PD-1 + pyrotinib

PD-1 + pyrotinib is a combination therapy consisting of a programmed cell death protein 1 (PD-1) inhibitor and pyrotinib, an oral irreversible pan-ErbB tyrosine kinase inhibitor. This combination is being investigated primarily for the treatment of cancers with HER2 alterations, such as HER2-positive gastric or gastroesophageal junction adenocarcinoma and HER2-mutant non-small cell lung cancer (NSCLC), particularly in patients who have failed prior chemotherapy. The rationale for this combination lies in targeting both immune checkpoints (via PD-1 inhibition) to enhance anti-tumor immunity and directly inhibiting tumor growth signaling pathways mediated by the ErbB family receptors (HER1/EGFR, HER2, and HER4) through pyrotinib. Early-phase clinical trials have shown promising efficacy and manageable safety profiles for this regimen[1][3][9].

Other names

PD-1 inhibitor + pyrotinibPD-1 Combined With PyrotinibPD1 Combined With PyrotinibPD 1 Combined With Pyrotinib